Testosterone Enanthate in Men 65 and Older: Developmental and Physiological Impact

Why Testosterone Levels Fall After 65

Total serum testosterone declines at roughly 1 to 2% per year beginning in the fourth decade, and free testosterone falls faster because sex hormone-binding globulin (SHBG) rises with age. By age 70, a substantial proportion of men meet biochemical criteria for hypogonadism.

The Scope of Age-Related Androgen Decline

Population data from the European Male Ageing Study (N=3,369) found that 2.1% of men aged 40 to 79 met combined symptomatic and biochemical criteria for late-onset hypogonadism, with prevalence rising steeply above age 70 [1]. Symptoms cluster into three domains: sexual (reduced libido, erectile dysfunction, fewer morning erections), somatic (loss of muscle mass, increased fat mass, fatigue), and psychological (depressed mood, poor concentration).

The Baltimore Longitudinal Study of Aging documented a mean total testosterone decline of approximately 110 ng/dL per decade after age 50 [2]. This is not a disease in the classical sense. It is a predictable physiological transition that crosses into clinical territory only when symptoms co-occur with confirmed low levels.

How Testosterone Enanthate Is Used in This Age Group

Testosterone enanthate is an esterified androgen given by intramuscular or subcutaneous injection. After injection, the ester is cleaved by plasma esterases, releasing free testosterone over 7 to 14 days. Typical clinical dosing in geriatric men starts at 100 to 200 mg every 1 to 2 weeks, titrated to achieve a mid-cycle trough total testosterone of 400 to 700 ng/dL [3].

The prolonged half-life of testosterone enanthate (approximately 4.5 days) produces a supraphysiologic peak in the first 2 to 3 days post-injection, followed by a gradual decline. This peak-to-trough swing is wider than with daily topical gels or testosterone undecanoate injections. For men over 65, narrowing that swing through more frequent, smaller doses may reduce cardiovascular and hematologic exposure.

Lean Body Mass and Physical Function

Testosterone enanthate increases lean body mass by stimulating muscle protein synthesis through androgen receptor activation in skeletal muscle. The magnitude of this effect in men over 65 is smaller than in younger men but is measurable.

Evidence from the Testosterone Trials

The Testosterone Trials (TTrials) were seven coordinated placebo-controlled RCTs enrolling 790 men aged 65 and older with confirmed low testosterone (below 275 ng/dL) and at least one symptom domain [4]. Participants received testosterone gel calibrated to achieve levels of 500 ng/dL (not injectable enanthate specifically), but the pharmacodynamic findings translate to equivalent serum exposures achieved by injection.

The physical function trial within TTrials found a statistically significant increase in 6-minute walk distance in the testosterone arm, though the improvement did not reach the pre-specified clinically meaningful threshold of 50 meters [4]. Lean mass increased by a mean of 1.6 kg more than placebo over 12 months.

Grip Strength and Functional Outcomes

Grip strength improved modestly. A 2019 Cochrane systematic review of testosterone therapy in men over 60 (32 RCTs, N=2,351) found a mean increase in grip strength of 1.6 kg (95% CI 0.4 to 2.8 kg) compared with placebo [5]. That is a real but modest signal. Falls risk and stair-climbing speed showed no statistically significant benefit across trials.

The 2018 Endocrine Society Clinical Practice Guideline states: "We suggest against testosterone therapy in men with age-related decline in testosterone who do not have clinical signs and symptoms of androgen deficiency" [3]. Physical function gains alone do not justify treatment absent confirmed hypogonadism with symptoms.

Bone Density and Fracture Risk

Bone mineral density responds to testosterone therapy in older men, and the TTrials bone sub-trial provides the clearest geriatric-specific evidence.

Volumetric BMD Data from TTrials

The TTrials bone trial enrolled 211 men from the main cohort and measured volumetric BMD by quantitative CT [6]. At 12 months, estimated volumetric BMD of the spine increased by 7.5% in the testosterone group vs. 0.3% in placebo (P<0.001). Trabecular bone score and hip BMD also improved significantly [6].

These are large effect sizes for a 12-month pharmacological intervention. For context, alendronate 70 mg weekly produces roughly 5 to 8% lumbar BMD increases over 3 years in osteoporotic men [7]. Testosterone's bone effect in this trial was driven partly by aromatization of testosterone to estradiol, which is the principal androgen-pathway mediator of bone resorption suppression in men.

Fracture Data Gaps

No large RCT of testosterone in men over 65 has reported fracture reduction as a primary endpoint. The TTrials bone trial was not powered for fracture outcomes. Prescribers should not use testosterone as a primary osteoporosis treatment when bisphosphonates or denosumab have established fracture-reduction evidence in men.

Sexual Function and Mood

Sexual function is the outcome domain with the most consistent benefit signal across trials of testosterone in older men.

TTrials Sexual Function Trial

The TTrials sexual function trial (N=470) found that testosterone increased sexual activity, sexual desire, and erectile function scores significantly compared to placebo over 12 months [4]. The proportion of men reporting increased sexual desire was 46.3% in the testosterone arm vs. 27.8% placebo. Erectile function domain scores on the IIEF scale improved by a mean of 2.6 points more than placebo.

This effect size is smaller than phosphodiesterase-5 inhibitors but additive when hypogonadism co-exists with erectile dysfunction. A 2016 NEJM paper from the TTrials reported: "Testosterone treatment increased sexual activity and desire and improved erectile function" [8].

Mood and Cognitive Function

The TTrials vitality trial found no significant improvement in energy (FACIT-Fatigue scale) or depressive symptoms (PHQ-9) compared with placebo [4]. The cognitive function sub-trial likewise showed no significant benefit in verbal memory or other cognitive domains at 12 months [9].

Men presenting with depressive symptoms or fatigue as their primary complaint should not receive testosterone as first-line therapy absent confirmed hypogonadism. The absence of cognitive benefit matters for geriatric prescribing because cognitive decline is common in this age group and testosterone is sometimes promoted informally as a neuroprotective agent.

Cardiovascular Safety

Cardiovascular safety is the most debated area of testosterone therapy in older men. Evidence from the past decade has clarified the picture substantially.

TRAVERSE Trial

The TRAVERSE trial (N=5,204, mean age 63.6 years) was a randomized, double-blind, placebo-controlled trial powered specifically for cardiovascular safety in men with hypogonadism and elevated cardiovascular risk or established cardiovascular disease [10]. Testosterone gel (not enanthate specifically) was titrated to 350 to 750 ng/dL. At median 33 months follow-up, testosterone was non-inferior to placebo for major adverse cardiovascular events (MACE): 7.0% vs. 7.3% (hazard ratio 0.96, 95% CI 0.78 to 1.17) [10].

This was the definitive answer to the cardiovascular controversy that began with the 2010 Basaria trial, which was halted early due to excess cardiac events in a high-risk elderly cohort [11]. TRAVERSE used a broader, better-powered design and showed no MACE excess.

Atrial Fibrillation Signal

TRAVERSE did identify a higher incidence of atrial fibrillation in the testosterone arm: 3.5% vs. 2.4% (hazard ratio 1.49, 95% CI 1.18 to 1.92) [10]. Pulmonary embolism was also numerically higher. The FDA issued a class warning on testosterone products regarding cardiovascular risk, and prescribers should discuss atrial fibrillation risk explicitly with men over 65, particularly those with pre-existing structural heart disease.

Hematocrit and Polycythemia

Testosterone enanthate stimulates erythropoietin production, raising red cell mass. In geriatric men, polycythemia (hematocrit above 52 to 54%) occurs in 3 to 18% of treated patients depending on dose, baseline hemoglobin, altitude of residence, and concurrent sleep apnea [3]. Polycythemia raises blood viscosity and may increase the risk of venous thromboembolism. The Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after initiation and withholding testosterone if hematocrit exceeds 54% [3].

Prostate Safety

Testosterone does not cause prostate cancer, but it may accelerate growth of pre-existing occult carcinoma by supplying androgen to androgen-sensitive cells.

PSA Monitoring Protocol

The Endocrine Society guideline recommends a prostate-specific antigen (PSA) check and digital rectal exam before initiating therapy in men over 40 [3]. In the first year of therapy, PSA should be re-checked at 3 to 6 months. A rise of more than 1.4 ng/mL over 12 months, or an absolute PSA above 4.0 ng/mL (above 3.0 ng/mL in high-risk men), warrants urology referral before continuing therapy.

Across the TTrials, testosterone did not significantly increase PSA at 12 months compared to placebo [4]. The absolute PSA difference was 0.09 ng/mL. Long-term prostate cancer risk over decades remains incompletely characterized because no testosterone RCT has run beyond 3 years.

Dosing and Monitoring Framework for Men 65 and Older

Geriatric prescribing of testosterone enanthate requires adjustments relative to younger men. The goal is to restore testosterone to the mid-normal range for young-adult men (400 to 700 ng/dL trough), not to maximize levels.

Initial Dosing Approach

A reasonable starting regimen is testosterone enanthate 100 mg IM every 7 days or 200 mg IM every 14 days. The 7-day interval reduces peak-trough swings and may lower hematocrit excursions. Subcutaneous injection at the same doses is increasingly used in office and self-injection settings, with comparable pharmacokinetics and less injection site pain.

Dose adjustments should occur no sooner than 6 weeks after initiation, after at least two steady-state trough levels are obtained. Trough sampling should occur 7 days after a 14-day dose or 6 to 7 days after a 7-day dose.

Monitoring Schedule

| Timepoint | Labs and Assessments | |---|---| | Baseline | Total testosterone (two morning samples), free testosterone, LH, FSH, CBC, PSA, hematocrit, metabolic panel | | 3 months | Total testosterone (trough), hematocrit, PSA | | 6 months | Total testosterone (trough), hematocrit, PSA, BMD if baseline low | | 12 months | Full repeat of baseline panel, review symptom scores | | Annually thereafter | Total testosterone, hematocrit, PSA, CBC |

If hematocrit rises above 52%, reduce dose or extend dosing interval. If it exceeds 54%, hold therapy until hematocrit normalizes, then restart at a lower dose [3].

Contraindications Specific to Older Men

Absolute contraindications in men 65 and older include: active or suspected prostate cancer, active breast cancer, hematocrit above 54%, and severe untreated obstructive sleep apnea (which worsens with testosterone through effects on upper airway musculature and ventilatory drive) [3]. Relative contraindications include untreated severe lower urinary tract symptoms (IPSS above 19) and uncontrolled heart failure.

Distinguishing Normal Aging from Pathological Hypogonadism

Not every low testosterone measurement in a man over 65 requires treatment. Transient suppression occurs with acute illness, caloric restriction, opioid use, and glucocorticoid therapy.

Diagnostic Criteria

The Endocrine Society defines biochemical hypogonadism as two separate morning total testosterone measurements below 300 ng/dL, with symptoms [3]. The American Urological Association endorses a threshold of 300 ng/dL [12]. SHBG rises with age, so free testosterone calculated by the Vermeulen equation (or measured by equilibrium dialysis) may diagnose hypogonadism in men whose total testosterone falls in the 300 to 400 ng/dL gray zone.

Symptoms must accompany the biochemical finding. The most specific symptoms for hypogonadism are loss of morning erections, reduced sexual desire, and loss of body hair. Non-specific symptoms (fatigue, depressed mood, poor concentration) overlap heavily with depression, obstructive sleep apnea, hypothyroidism, and normal aging itself [3].

The Role of LH and FSH

In men over 65, distinguishing primary testicular failure (high LH and FSH) from secondary hypogonadism (low or normal LH and FSH) changes the diagnostic workup. Secondary hypogonadism in an older man warrants pituitary MRI to exclude a macro-adenoma before starting testosterone. Primary hypogonadism does not.

Body Composition and Metabolic Effects

Testosterone therapy in hypogonadal men over 65 produces measurable shifts in body composition, even when physical function gains are modest.

Fat Mass and Metabolic Markers

The TTrials reported a mean reduction in total fat mass of 1.4 kg more than placebo at 12 months [4]. Visceral adipose tissue measured by CT decreased significantly in the testosterone arm. Insulin sensitivity improved modestly, with fasting glucose and HbA1c showing small but statistically significant reductions in some sub-trials.

A 2020 meta-analysis in JCEM (17 RCTs, N=1,031, mean age 60.3 years) found that testosterone therapy reduced fat mass by a weighted mean of 1.7 kg (95% CI 1.0 to 2.4 kg) and increased lean mass by 1.9 kg (95% CI 1.4 to 2.4 kg) compared with placebo [13]. These metabolic changes may reduce cardiometabolic risk over longer timeframes, though no trial has demonstrated hard cardiovascular event reduction through body composition improvement alone.

Insulin Resistance in Older Men

Testosterone deficiency in older men correlates with metabolic syndrome, insulin resistance, and type 2 diabetes. Whether testosterone therapy reduces diabetes incidence is unproven. The TRAVERSE trial did not report diabetes incidence as a pre-specified outcome [10]. Replacing testosterone to normal physiological levels in hypogonadal diabetic men may modestly improve HbA1c, though insulin or GLP-1 receptor agonist therapy remains the primary tool for glycemic management.